<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04523363</url>
  </required_header>
  <id_info>
    <org_study_id>H00021261</org_study_id>
    <nct_id>NCT04523363</nct_id>
  </id_info>
  <brief_title>Metformin Versus Standard of Care Treatment in Pregnant Women With Prediabetes</brief_title>
  <official_title>Metformin Versus Standard of Care Treatment in Pregnant Women With Prediabetes: A Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gianna Wilkie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Massachusetts, Worcester</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess if metformin reduces adverse outcomes associated with&#xD;
      prediabetes in pregnancy. Our hypothesis is that pregnant women with prediabetes who are&#xD;
      treated with metformin will show a greater reduction in large for gestational age infants at&#xD;
      birth compared to women treated with the standard of care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Women in pregnancy are routinely screened for diabetes in the first trimester and those who&#xD;
      fall into the prediabetes category by hemoglobin A1c level of 5.7 to 6.4%, fasting plasma&#xD;
      glucose of greater than or equal to 100 to 125, or oral glucose tolerance test of greater&#xD;
      than or equal to 140 to less than 200 before 14 weeks gestation will be approached for&#xD;
      consent in our randomized trial.&#xD;
&#xD;
      Once consent is obtained, the subjects will be randomized 1:1 into two parallel groups, the&#xD;
      metformin treatment group and the standard of care treatment group (routine prenatal care). A&#xD;
      random number generator will allocate the participants to the study groups.&#xD;
&#xD;
      Women taking metformin will continue twice daily dosing for the duration of their pregnancy&#xD;
      after randomization. Those in the standard of care group will receive routine prenatal care.&#xD;
      Both groups will undergo routine gestational diabetes testing by 28 weeks. Obstetric,&#xD;
      maternal, and neonatal outcomes will then be assessed of both groups until the 6 week&#xD;
      postpartum visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a prospective, single center, randomized study evaluating metformin in the treatment of pregnant women with prediabetes on maternal and neonatal outcomes.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Those assessing the outcomes from the medical chart will be blinded to the randomization process and the assigned study arm. Patients, the primary investigator, and their care providers will be aware of their treatment status.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Birth Weight</measure>
    <time_frame>At Birth</time_frame>
    <description>Used to determine large for gestational age status</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants needing Cesarean Section</measure>
    <time_frame>At Delivery</time_frame>
    <description>Number of Participants with Cesarean Section</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Postpartum Hemorrhage</measure>
    <time_frame>At Delivery</time_frame>
    <description>Estimated or quantitative blood loss greater than 1000 mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Development of Pregnancy Induced Hypertension</measure>
    <time_frame>Through study completion, starting at 14 weeks until delivery</time_frame>
    <description>Blood pressure, serum laboratory analysis, and urine protein would be assessed for diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of Gestational Diabetes</measure>
    <time_frame>Assessed at 28 weeks of pregnancy</time_frame>
    <description>A glucose tolerance test would be conducted at 28 weeks of pregnancy to diagnose diabetes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal Weight Gain in Pregnancy</measure>
    <time_frame>At enrollment and last prenatal visit, starting at 14 weeks until delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy Outcome</measure>
    <time_frame>Through study completion, starting at 14 weeks until delivery</time_frame>
    <description>Number of Participants with Stillbirth, livebirth, pregnancy loss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Preterm birth</measure>
    <time_frame>At delivery</time_frame>
    <description>Less than 37 week delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Intensive Care Unit Admission</measure>
    <time_frame>At delivery and within first 2 days of life</time_frame>
    <description>Admission to level 2 or greater neonatal ICU and length of stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apgar Score at Birth</measure>
    <time_frame>At delivery</time_frame>
    <description>&lt;6 at 1 and 5 minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Neonatal Birth Trauma</measure>
    <time_frame>At Delivery</time_frame>
    <description>Brachial plexus injury</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Shoulder Dystocia</measure>
    <time_frame>At Delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Neonatal Hypoglycemia</measure>
    <time_frame>Within first 2 days of life</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Neonatal Respiratory Distress</measure>
    <time_frame>At Delivery</time_frame>
    <description>Requiring 2 or more hours of respiratory support or oxygen with associated diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Neonatal Hyperbilirubinemia</measure>
    <time_frame>Within first 2 days of life</time_frame>
    <description>Requiring phototherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants requiring Neonatal Intubation</measure>
    <time_frame>At Delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Cooling</measure>
    <time_frame>Within first 2 days of life</time_frame>
    <description>Need for neonatal cooling within first 48 hours of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Umbilical Cord Blood Level of C-peptide</measure>
    <time_frame>At Birth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Umbilical Cord Blood Level of Leptin</measure>
    <time_frame>At Birth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Umbilical Cord Blood Level of Insulin</measure>
    <time_frame>At Birth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placental Pathology</measure>
    <time_frame>At Birth</time_frame>
    <description>Assessing for malperfusion pathology</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Prediabetes; Complicating Pregnancy</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study subjects will be randomized to the metformin medication arm. They will take a 500 mg tablet orally twice a day starting at 14 weeks of pregnancy until delivery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Study subjects will be randomized to standard of care and receive routine prenatal care without further intervention for their prediabetes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Maximum dosage of 500 mg tablets 2 times a day (with each meal)</description>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnant women with hemoglobin A1c of 5.7 to 6.4%, fasting plasma glucose of greater&#xD;
             than or equal to 100 to 125, or oral glucose tolerance test of greater than or equal&#xD;
             to 140 to less than 200 before 14 weeks gestation&#xD;
&#xD;
          -  Pregnancy and delivery care obtained at University of Massachusetts (UMass) Memorial&#xD;
             Medical Center&#xD;
&#xD;
          -  Patients able to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pre-existing diabetes diagnosis as assessed at visit in the first trimester by history&#xD;
             or by laboratory evaluation as listed above&#xD;
&#xD;
          -  Presence of contra-indication to metformin (liver, renal, or heart failure) or&#xD;
             sensitivity to metformin&#xD;
&#xD;
          -  Participants who are under the age of 18&#xD;
&#xD;
          -  Multiple Pregnancy&#xD;
&#xD;
          -  Patients already taking metformin for other indications&#xD;
&#xD;
          -  Fetal defect noted on early dating ultrasound&#xD;
&#xD;
          -  Miscarriage before randomization&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gianna L Wilkie, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMass Memorial Health Care</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gianna L Wilkie, MD</last_name>
    <phone>508-334-4067</phone>
    <email>Gianna.Wilkie@umassmemorial.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Heidi Leftwich, DO</last_name>
    <email>Heidi.Leftwich@umassmemorial.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Massachusetts Memorial Medical Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Gianna L Wilkie, MD</last_name>
      <phone>508-334-4067</phone>
      <email>Gianna.Wilkie@umassmemorial.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Peterson C, Grosse SD, Li R, Sharma AJ, Razzaghi H, Herman WH, Gilboa SM. Preventable health and cost burden of adverse birth outcomes associated with pregestational diabetes in the United States. Am J Obstet Gynecol. 2015 Jan;212(1):74.e1-9. doi: 10.1016/j.ajog.2014.09.009. Epub 2014 Oct 28.</citation>
    <PMID>25439811</PMID>
  </reference>
  <reference>
    <citation>Lawrence JM, Contreras R, Chen W, Sacks DA. Trends in the prevalence of preexisting diabetes and gestational diabetes mellitus among a racially/ethnically diverse population of pregnant women, 1999-2005. Diabetes Care. 2008 May;31(5):899-904. doi: 10.2337/dc07-2345. Epub 2008 Jan 25.</citation>
    <PMID>18223030</PMID>
  </reference>
  <reference>
    <citation>Temple R, Murphy H. Type 2 diabetes in pregnancy - An increasing problem. Best Pract Res Clin Endocrinol Metab. 2010 Aug;24(4):591-603. doi: 10.1016/j.beem.2010.05.011. Review.</citation>
    <PMID>20832738</PMID>
  </reference>
  <reference>
    <citation>Lee AM, Fermin CR, Filipp SL, Gurka MJ, DeBoer MD. Examining trends in prediabetes and its relationship with the metabolic syndrome in US adolescents, 1999-2014. Acta Diabetol. 2017 Apr;54(4):373-381. doi: 10.1007/s00592-016-0958-6. Epub 2017 Jan 9.</citation>
    <PMID>28070750</PMID>
  </reference>
  <reference>
    <citation>Chen L, Pocobelli G, Yu O, Shortreed SM, Osmundson SS, Fuller S, Wartko PD, Mcculloch D, Warwick S, Newton KM, Dublin S. Early Pregnancy Hemoglobin A1C and Pregnancy Outcomes: A Population-Based Study. Am J Perinatol. 2019 Aug;36(10):1045-1053. doi: 10.1055/s-0038-1675619. Epub 2018 Nov 30.</citation>
    <PMID>30500961</PMID>
  </reference>
  <reference>
    <citation>Professional Practice Committee for the Standards of Medical Care in Diabetes-2016. Diabetes Care. 2016 Jan;39 Suppl 1:S107-8. doi: 10.2337/dc16-S018.</citation>
    <PMID>26696673</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 18, 2020</study_first_submitted>
  <study_first_submitted_qc>August 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2020</study_first_posted>
  <last_update_submitted>March 4, 2021</last_update_submitted>
  <last_update_submitted_qc>March 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Massachusetts, Worcester</investigator_affiliation>
    <investigator_full_name>Gianna Wilkie</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>maternal outcomes</keyword>
  <keyword>neonatal outcomes</keyword>
  <keyword>metformin</keyword>
  <keyword>prediabetes</keyword>
  <keyword>pregnancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregnancy Complications</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

